Arialys Therapeutics, a La Jolla, CA-based biotechnology company advancing therapeutics for autoimmune neuropsychiatry, raised $58M in Seed funding.
The round saw participation from Avalon BioVentures, Catalys Pacific, and MPM BioImpact, along with Johnson & Johnson Innovation – JJDC, Inc. and Alexandria Venture Investments.
The company intends to use the funds to advance new precision medicines that specifically block pathogenic autoantibodies in the central nervous system (CNS) and expand the treatment possibilities for neuropsychiatric diseases driven by autoimmunity.
Led by Jay Lichter, PhD, President and CEO, and Mitsuyuki “Mickey” Matsumoto, PhD, Scientific Founder and Chief Scientific Officer, Arialys Therapeutics is developing new precision medicines to block pathogenic autoantibodies in the brain and expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Its lead therapeutic ART5803 is a therapeutic antibody designed to treat ANRE by blocking NMDAR autoantibodies. Arialys has generated promising preclinical data in a nonhuman primate disease model confirming ART5803 reverses encephalitis and decreases the behavioral symptoms caused by NMDAR autoantibody pathogenicity in the brain.
The company has received orphan drug designation from the U.S. Food and Drug Administration for ART5803 for the treatment of ANRE. Arialys purchased ART5803 from Astellas Pharma.
FinSMEs
13/09/2023